Xeris Biopharma Holdings Inc. Company Profile

Direct Answer

Xeris Biopharma Holdings Inc. (XERS) is a U.S.-listed company in Swoopr's Dow Jones U.S. Total Stock Market research set. SEC EDGAR lists its industry as Pharmaceutical Preparations. This profile is a research framework: it does not state company-specific segments, products, management, financial figures or historical claims that have not been verified against primary sources.

The research objective is to determine how Xeris Biopharma Holdings Inc. converts pharmaceuticals, biotechnology, medical devices, diagnostics, care delivery or health-services infrastructure into durable per-share cash generation. The page therefore emphasizes revenue mechanics, customers, margins, capital intensity, cash conversion, competition, risks, scenario analysis and monitoring signals rather than a stock-price prediction.

What Do the Latest SEC Filings Show for Xeris Biopharma Holdings?

These are figures Xeris Biopharma Holdings reported in its own SEC filings, read from the SEC's XBRL data, so the page has a fixed starting point before any of the research questions below. They describe reported history and are not a forecast.

Source: SEC EDGAR: Xeris Biopharma Holdings, Inc. Form 10-K filed March 2, 2026.

Company Snapshot

Unverified fields such as current CEO, headquarters, employee count, CIK, fiscal year end, reported segments and current financial figures are intentionally omitted from this profile.

What the Company Does

Investors studying Xeris Biopharma Holdings Inc. (XERS) should treat the company as an operating system of customers, assets, costs, capital and competitive choices, not merely as a ticker. SEC EDGAR lists the industry of Xeris Biopharma Holdings Inc. as Pharmaceutical Preparations. Within that boundary, the analytical starting point is the sector's typical economic chain: pharmaceuticals, biotechnology, medical devices, diagnostics, care delivery or health-services infrastructure. The distinction is important because accounting results can move before, or after, the operating drivers that ultimately determine cash returns. A strong review should test procedure or prescription volumes, clinical and regulatory milestones, and pipeline milestones together rather than treating any one figure as decisive.

How the Company Makes Money

Investors studying Xeris Biopharma Holdings Inc. (XERS) should treat the company as an operating system of customers, assets, costs, capital and competitive choices, not merely as a ticker. For Xeris Biopharma Holdings Inc., start by translating reported revenue into the operating causes behind it. In this sector those causes often include reimbursement, new indications, capacity and commercial execution, and product adoption. A disciplined review therefore asks what changed operationally, how much capital was required, and whether the change can repeat. The same discipline should be applied to pipeline milestones, procedure or prescription volumes when relevant, and operating margin, because a favorable top-line result can have very different implications depending on margin, capital intensity and cash conversion.

Revenue Engine

A useful way to analyze Xeris Biopharma Holdings Inc. (XERS) is to begin with the operating mechanism rather than the share price. The customer map for Xeris Biopharma Holdings Inc. should be built from disclosed end markets rather than assumed from its sector label. Likely research categories to validate include payers, pharmacies, government health programs and research organizations, and patients. The analytical question is why those customers choose the offering, how concentrated the relationship is, and whether purchasing behavior is recurring or transactional. The objective is not to forecast a stock price; it is to understand what evidence would strengthen or weaken the business case. Evidence of switching costs, contractual duration, distribution reach or product criticality should be cited directly when present.

• Product Adoption, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.
• Procedure Or Prescription Volumes, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.
• Clinical And Regulatory Milestones, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.

Business Segments and Reporting Map

A useful way to analyze Xeris Biopharma Holdings Inc. (XERS) is to begin with the operating mechanism rather than the share price. The most useful risk work on Xeris Biopharma Holdings Inc. links a risk to a measurable transmission mechanism. For this sector, relevant categories can include reimbursement pressure, product safety, customer concentration, and litigation. A risk matters through the revenue, margin, cash-flow or balance-sheet path it could affect, so it is not listed merely because it appears in a filing. The objective is not to forecast a stock price; it is to understand what evidence would strengthen or weaken the business case. Monitoring should therefore connect each risk to a leading indicator or disclosure that can be checked over time.

Products, Services and Commercial Offerings

A useful way to analyze Xeris Biopharma Holdings Inc. (XERS) is to begin with the operating mechanism rather than the share price. Supply-chain analysis for Xeris Biopharma Holdings Inc. should identify where bargaining power sits from upstream inputs through end demand. A practical map begins with provider and payer channels, moves through patients and care settings and scientific research and intellectual property, and ends with regulated manufacturing. Company-specific suppliers or customers should only be named when supported by filings or other authoritative evidence. The distinction is important because accounting results can move before, or after, the operating drivers that ultimately determine cash returns. Concentration, lead times, geographic dependence and substitution difficulty are more informative than a decorative list of counterparties.

Customers and Demand Structure

Research on Xeris Biopharma Holdings Inc. (XERS) is most productive when the business model, cash-flow engine and risk structure are separated from market sentiment. Macro sensitivity should be tested rather than assumed. Variables worth checking for Xeris Biopharma Holdings Inc. include interest rates for development-stage issuers, demographics, health-care utilization, and government reimbursement policy. The goal is to determine whether these variables affect unit demand, pricing, financing cost, working capital, asset utilization or customer solvency. The objective is not to forecast a stock price; it is to understand what evidence would strengthen or weaken the business case. A robust dossier distinguishes direct exposure from second-order correlations and avoids implying that every macro variable is equally important.

• Providers, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.
• Hospitals, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.
• Payers, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.

Geographic Exposure

Research on Xeris Biopharma Holdings Inc. (XERS) is most productive when the business model, cash-flow engine and risk structure are separated from market sentiment. Capital allocation is where operating performance is converted into per-share outcomes. For Xeris Biopharma Holdings Inc., follow where capital goes: internal investment, capital expenditures, acquisitions, divestitures, dividends, repurchases, debt changes and equity issuance. In a business like this, operating margin and free cash flow can be especially informative when interpreted alongside returns on incremental capital. The distinction is important because accounting results can move before, or after, the operating drivers that ultimately determine cash returns. The right question is not whether management spent more or less, but whether each use of capital improved durable cash-generation capacity per share.

Business Model

The investment case for Xeris Biopharma Holdings Inc. (XERS) becomes clearer when revenue drivers, cost behavior, balance-sheet demands and competitive constraints are examined together. The financial statements of Xeris Biopharma Holdings Inc. should be read as one connected system. Income-statement growth means more when it is read against balance-sheet investment and cash-flow conversion: compare changes in procedure or prescription volumes when relevant with operating margin, free cash flow, and product concentration. Health-care economics are unusually dependent on evidence, regulation and reimbursement. Reported growth must be connected to product durability, exclusivity, clinical value, payer acceptance, manufacturing reliability and the cost of sustaining the next generation of products. The objective is not to forecast a stock price; it is to understand what evidence would strengthen or weaken the business case. Persistent divergence between earnings and cash generation deserves an explanation grounded in working capital, capital expenditures, non-cash compensation, acquisitions or other company-specific factors.

For Xeris Biopharma Holdings Inc., verify the actual revenue mechanisms, recurring, transactional, subscription, licensing, advertising, spread, fee, product, manufacturing, service or another model, and document only the mechanisms supported by current filings. Health-care economics are unusually dependent on evidence, regulation and reimbursement. Reported growth must be connected to product durability, exclusivity, clinical value, payer acceptance, manufacturing reliability and the cost of sustaining the next generation of products.

Company Economics

Research on Xeris Biopharma Holdings Inc. (XERS) is most productive when the business model, cash-flow engine and risk structure are separated from market sentiment. SEC EDGAR lists the industry of Xeris Biopharma Holdings Inc. as Pharmaceutical Preparations. Within that boundary, the analytical starting point is the sector's typical economic chain: pharmaceuticals, biotechnology, medical devices, diagnostics, care delivery or health-services infrastructure. The distinction is important because accounting results can move before, or after, the operating drivers that ultimately determine cash returns. A strong review should test clinical and regulatory milestones, reimbursement, and gross margin together rather than treating any one figure as decisive.

How to Read the Income Statement

Investors studying Xeris Biopharma Holdings Inc. (XERS) should treat the company as an operating system of customers, assets, costs, capital and competitive choices, not merely as a ticker. For Xeris Biopharma Holdings Inc., start by translating reported revenue into the operating causes behind it. In this sector those causes often include product adoption, procedure or prescription volumes, clinical and regulatory milestones, and reimbursement. This matters because headline growth can look similar while the quality of that growth differs materially. The same discipline should be applied to product concentration, return on invested capital, and organic revenue growth, because a favorable top-line result can have very different implications depending on margin, capital intensity and cash conversion.

How to Read the Balance Sheet

A useful way to analyze Xeris Biopharma Holdings Inc. (XERS) is to begin with the operating mechanism rather than the share price. The customer map for Xeris Biopharma Holdings Inc. should be built from disclosed end markets rather than assumed from its sector label. Likely research categories to validate include government health programs and research organizations, patients, providers, and hospitals. The analytical question is why those customers choose the offering, how concentrated the relationship is, and whether purchasing behavior is recurring or transactional. This matters because headline growth can look similar while the quality of that growth differs materially. Evidence of switching costs, contractual duration, distribution reach or product criticality should be cited directly when present.

How to Read Cash Flow

For Xeris Biopharma Holdings Inc. (XERS), the central analytical task is to connect reported financial results to the underlying drivers that can persist across cycles. The most useful risk work on Xeris Biopharma Holdings Inc. links a risk to a measurable transmission mechanism. For this sector, relevant categories can include litigation, manufacturing quality, clinical failure, and regulatory delay. A risk matters through the revenue, margin, cash-flow or balance-sheet path it could affect, so it is not listed merely because it appears in a filing. That framework helps separate durable improvement from temporary benefits created by pricing, mix, working capital or a favorable cycle. Monitoring should therefore connect each risk to a leading indicator or disclosure that can be checked over time.

Metrics That Matter Most

For Xeris Biopharma Holdings Inc. (XERS), the central analytical task is to connect reported financial results to the underlying drivers that can persist across cycles. Supply-chain analysis for Xeris Biopharma Holdings Inc. should identify where bargaining power sits from upstream inputs through end demand. A practical map begins with clinical development or engineering, moves through regulated manufacturing and provider and payer channels, and ends with scientific research and intellectual property. Company-specific suppliers or customers should only be named when supported by filings or other authoritative evidence. The objective is not to forecast a stock price; it is to understand what evidence would strengthen or weaken the business case. Concentration, lead times, geographic dependence and substitution difficulty are more informative than a decorative list of counterparties.

• Organic Revenue Growth, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.
• Gross Margin, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.
• Research And Development Spending, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.

Competitive Position

For Xeris Biopharma Holdings Inc. (XERS), the central analytical task is to connect reported financial results to the underlying drivers that can persist across cycles. Macro sensitivity should be tested rather than assumed. Variables worth checking for Xeris Biopharma Holdings Inc. include demographics, health-care utilization, government reimbursement policy, and employment and insurance coverage. The goal is to determine whether these variables affect unit demand, pricing, financing cost, working capital, asset utilization or customer solvency. The distinction is important because accounting results can move before, or after, the operating drivers that ultimately determine cash returns. A robust dossier distinguishes direct exposure from second-order correlations and avoids implying that every macro variable is equally important.

Industry Position

Research on Xeris Biopharma Holdings Inc. (XERS) is most productive when the business model, cash-flow engine and risk structure are separated from market sentiment. Capital allocation is where operating performance is converted into per-share outcomes. For Xeris Biopharma Holdings Inc., follow where capital goes: internal investment, capital expenditures, acquisitions, divestitures, dividends, repurchases, debt changes and equity issuance. In a business like this, pipeline milestones and procedure or prescription volumes when relevant can be especially informative when interpreted alongside returns on incremental capital. A disciplined review therefore asks what changed operationally, how much capital was required, and whether the change can repeat. The right question is not whether management spent more or less, but whether each use of capital improved durable cash-generation capacity per share.

Supply Chain and Dependencies

A useful way to analyze Xeris Biopharma Holdings Inc. (XERS) is to begin with the operating mechanism rather than the share price. The financial statements of Xeris Biopharma Holdings Inc. should be read as one connected system. Income-statement growth means more when it is read against balance-sheet investment and cash-flow conversion: compare changes in product concentration with return on invested capital, organic revenue growth, and research and development spending. Health-care economics are unusually dependent on evidence, regulation and reimbursement. Reported growth must be connected to product durability, exclusivity, clinical value, payer acceptance, manufacturing reliability and the cost of sustaining the next generation of products. The distinction is important because accounting results can move before, or after, the operating drivers that ultimately determine cash returns. Persistent divergence between earnings and cash generation deserves an explanation grounded in working capital, capital expenditures, non-cash compensation, acquisitions or other company-specific factors.

• Clinical Development Or Engineering, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.
• Regulated Manufacturing, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.
• Provider And Payer Channels, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.

Economic Sensitivity

The investment case for Xeris Biopharma Holdings Inc. (XERS) becomes clearer when revenue drivers, cost behavior, balance-sheet demands and competitive constraints are examined together. SEC EDGAR lists the industry of Xeris Biopharma Holdings Inc. as Pharmaceutical Preparations. Within that boundary, the analytical starting point is the sector's typical economic chain: pharmaceuticals, biotechnology, medical devices, diagnostics, care delivery or health-services infrastructure. A disciplined review therefore asks what changed operationally, how much capital was required, and whether the change can repeat. A strong review should test capacity and commercial execution, product adoption, and cash runway for pre-profit issuers together rather than treating any one figure as decisive.

• Employment And Insurance Coverage, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.
• Interest Rates For Development-Stage Issuers, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.
• Demographics, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.

Capital Allocation

For Xeris Biopharma Holdings Inc. (XERS), the central analytical task is to connect reported financial results to the underlying drivers that can persist across cycles. The customer map for Xeris Biopharma Holdings Inc. should be built from disclosed end markets rather than assumed from its sector label. Likely research categories to validate include government health programs and research organizations, patients, providers, and hospitals. The analytical question is why those customers choose the offering, how concentrated the relationship is, and whether purchasing behavior is recurring or transactional. The distinction is important because accounting results can move before, or after, the operating drivers that ultimately determine cash returns. Evidence of switching costs, contractual duration, distribution reach or product criticality should be cited directly when present.

For Xeris Biopharma Holdings Inc., reconcile internal investment, acquisitions, divestitures, dividends, repurchases, debt changes and equity issuance. The useful question is whether each use of capital increases durable cash-generation capacity per share after considering risk and the opportunity cost of capital.

Growth Drivers

The investment case for Xeris Biopharma Holdings Inc. (XERS) becomes clearer when revenue drivers, cost behavior, balance-sheet demands and competitive constraints are examined together. The most useful risk work on Xeris Biopharma Holdings Inc. links a risk to a measurable transmission mechanism. For this sector, relevant categories can include patent or exclusivity loss, reimbursement pressure, product safety, and customer concentration. A risk matters through the revenue, margin, cash-flow or balance-sheet path it could affect, so it is not listed merely because it appears in a filing. This matters because headline growth can look similar while the quality of that growth differs materially. Monitoring should therefore connect each risk to a leading indicator or disclosure that can be checked over time.

• Procedure Or Prescription Volumes, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.
• Clinical And Regulatory Milestones, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.
• Reimbursement, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.

Risk Factors

The investment case for Xeris Biopharma Holdings Inc. (XERS) becomes clearer when revenue drivers, cost behavior, balance-sheet demands and competitive constraints are examined together. Supply-chain analysis for Xeris Biopharma Holdings Inc. should identify where bargaining power sits from upstream inputs through end demand. A practical map begins with clinical development or engineering, moves through regulated manufacturing and provider and payer channels, and ends with scientific research and intellectual property. Company-specific suppliers or customers should only be named when supported by filings or other authoritative evidence. This matters because headline growth can look similar while the quality of that growth differs materially. Concentration, lead times, geographic dependence and substitution difficulty are more informative than a decorative list of counterparties.

• Product Safety, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.
• Customer Concentration, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.
• Litigation, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.

Bull, Base and Bear Operating Framework

Research on Xeris Biopharma Holdings Inc. (XERS) is most productive when the business model, cash-flow engine and risk structure are separated from market sentiment. Macro sensitivity should be tested rather than assumed. Variables worth checking for Xeris Biopharma Holdings Inc. include health-care utilization, government reimbursement policy, employment and insurance coverage, and interest rates for development-stage issuers. The goal is to determine whether these variables affect unit demand, pricing, financing cost, working capital, asset utilization or customer solvency. The objective is not to forecast a stock price; it is to understand what evidence would strengthen or weaken the business case. A robust dossier distinguishes direct exposure from second-order correlations and avoids implying that every macro variable is equally important.

A bull case for Xeris Biopharma Holdings Inc. names the operating drivers that outperform, a base case describes normal execution, and a bear case identifies what deteriorates. Each case should use measurable business conditions rather than a target share price.

What Could Prove an Investment Thesis Wrong?

Investors studying Xeris Biopharma Holdings Inc. (XERS) should treat the company as an operating system of customers, assets, costs, capital and competitive choices, not merely as a ticker. Capital allocation is where operating performance is converted into per-share outcomes. For Xeris Biopharma Holdings Inc., follow where capital goes: internal investment, capital expenditures, acquisitions, divestitures, dividends, repurchases, debt changes and equity issuance. In a business like this, research and development spending and pipeline milestones can be especially informative when interpreted alongside returns on incremental capital. That framework helps separate durable improvement from temporary benefits created by pricing, mix, working capital or a favorable cycle. The right question is not whether management spent more or less, but whether each use of capital improved durable cash-generation capacity per share.

What Investors Commonly Misunderstand

The investment case for Xeris Biopharma Holdings Inc. (XERS) becomes clearer when revenue drivers, cost behavior, balance-sheet demands and competitive constraints are examined together. The financial statements of Xeris Biopharma Holdings Inc. should be read as one connected system. Income-statement growth means more when it is read against balance-sheet investment and cash-flow conversion: compare changes in gross margin with research and development spending, pipeline milestones, and operating margin. Health-care economics are unusually dependent on evidence, regulation and reimbursement. Reported growth must be connected to product durability, exclusivity, clinical value, payer acceptance, manufacturing reliability and the cost of sustaining the next generation of products. This matters because headline growth can look similar while the quality of that growth differs materially. Persistent divergence between earnings and cash generation deserves an explanation grounded in working capital, capital expenditures, non-cash compensation, acquisitions or other company-specific factors.

Common analytical errors for Xeris Biopharma Holdings Inc. can include treating sector averages as company facts, confusing revenue growth with cash-value creation, ignoring share issuance or acquisition effects, and assuming a favorable cycle is permanent. Replace these general cautions with issuer-specific misconceptions after primary-source enrichment.

What to Monitor

Research on Xeris Biopharma Holdings Inc. (XERS) is most productive when the business model, cash-flow engine and risk structure are separated from market sentiment. SEC EDGAR lists the industry of Xeris Biopharma Holdings Inc. as Pharmaceutical Preparations. Within that boundary, the analytical starting point is the sector's typical economic chain: pharmaceuticals, biotechnology, medical devices, diagnostics, care delivery or health-services infrastructure. A disciplined review therefore asks what changed operationally, how much capital was required, and whether the change can repeat. A strong review should test product adoption, procedure or prescription volumes, and organic revenue growth together rather than treating any one figure as decisive.

• Cash Runway For Pre-Profit Issuers, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.
• Product Concentration, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.
• Return On Invested Capital, For Xeris Biopharma Holdings Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength.

Key Takeaways

Investors studying Xeris Biopharma Holdings Inc. (XERS) should treat the company as an operating system of customers, assets, costs, capital and competitive choices, not merely as a ticker. The customer map for Xeris Biopharma Holdings Inc. should be built from disclosed end markets rather than assumed from its sector label. Likely research categories to validate include patients, providers, hospitals, and payers. The analytical question is why those customers choose the offering, how concentrated the relationship is, and whether purchasing behavior is recurring or transactional. That framework helps separate durable improvement from temporary benefits created by pricing, mix, working capital or a favorable cycle. Evidence of switching costs, contractual duration, distribution reach or product criticality should be cited directly when present.

Questions Investors Should Ask

For Xeris Biopharma Holdings Inc. (XERS), the central analytical task is to connect reported financial results to the underlying drivers that can persist across cycles. For Xeris Biopharma Holdings Inc., start by translating reported revenue into the operating causes behind it. In this sector those causes often include reimbursement, new indications, capacity and commercial execution, and product adoption. That framework helps separate durable improvement from temporary benefits created by pricing, mix, working capital or a favorable cycle. The same discipline should be applied to organic revenue growth, gross margin, and research and development spending, because a favorable top-line result can have very different implications depending on margin, capital intensity and cash conversion.

1. What two or three variables explain most changes in Xeris Biopharma Holdings Inc.'s revenue?
2. Which costs at Xeris Biopharma Holdings Inc. are fixed, variable, or investment for future growth?
3. What evidence shows that Xeris Biopharma Holdings Inc. has, or lacks, pricing power?
4. Which customers or channels matter most, and is concentration changing?
5. How well do reported earnings at Xeris Biopharma Holdings Inc. convert to cash?
6. How much reinvestment is required to sustain the competitive position?
7. Which KPI would give the earliest warning of deterioration?
8. How exposed is Xeris Biopharma Holdings Inc. to health-care utilization and government reimbursement policy?
9. Is capital allocation improving per-share economics?
10. What evidence would invalidate a positive long-term thesis?

FAQ

References

• S&P Dow Jones Indices: Dow Jones U.S. Total Stock Market Index. Index identity and methodology context.
• S&P Dow Jones Indices methodology materials. Eligibility and maintenance framework.
• SEC EDGAR. The SEC's company search is where to confirm Xeris Biopharma Holdings Inc.'s legal identity, filings, segments and risks, and to read its financial statements.